+1.74% for Novo Nordisk stock as US Wegovy demand tops one million patients

Traders Union
All News
Financial News
Novo Nordisk gains 1.74% after Q1 beat

Highlights

Novo Nordisk exceeded Q1 2026 forecasts with adjusted operating profit of 32.86 billion Danish kroner, fueled by rapid U.S. uptake of the oral Wegovy pill.
Management raised full-year guidance as over one million patients started Wegovy treatment since January, supporting strong forward demand despite rising competition.
Technically, $NVO trades with short-term bullish momentum but overbought indicators and a projected $44.90–$47.90 range suggest near-term consolidation or modest pullback.

Raised guidance and Wegovy uptake bolster demand despite rising competition

Novo Nordisk's Q1 2026 results exceeded expectations, with adjusted operating profit rising to 32.86 billion Danish kroner and revenue reaching $15.17 billion, driven by rapid adoption of its oral Wegovy pill in the United States. Management raised full-year guidance, narrowing the anticipated sales and operating profit decline, and highlighted that more than one million patients commenced Wegovy pill therapy since its January launch. While recent FDA approval of Eli Lilly’s oral obesity drug is intensifying competition, Novo Nordisk’s strong first-quarter performance and successful product launch are fueling demand and supporting the current upward price momentum.

Overbought signals persist as near-term base firms amid mild trend

On the technical front, NVO closed above its SMA-20 at $40.85 and SMA-50 at $38.83, while remaining below the longer-term SMA-200 at $49.78. The D1 Ichimoku Kijun level sits at $40.87, providing immediate support, with the current price structure reflecting a strong near-term base. MACD signals a buy, and the D1 RSI stands significantly overbought at 73.10. Both the Stoch RSI and CCI indicate overbought conditions, and the BBP at 4.10 confirms dominance by buyers. The Awesome Oscillator signals a bullish bias, but ADX at 18.07 suggests trend strength is only moderate. Today’s trading featured a gap up, with the price holding near the session’s lower end and moderate volatility seen as the market consolidates recent gains.

Sideways trade likely as overbought signals reduce rally odds

For the next five trading days, NVO is expected to fluctuate within a projected volatility band of $44.90 to $47.90. The probability of a further increase is low, with less than a 20% chance of an upside move. The baseline scenario is for NVO to oscillate sideways as recent overbought conditions unwind. A break above $47.31 could trigger a short-term rally toward $47.90, while failure to hold above immediate support at $40.87 could open the way for a decline toward the lower end of the range at $44.90.

Viktoras Karapetjanc, analyst at Traders Union, sees Novo Nordisk’s strong Q1 numbers and upbeat guidance as clear evidence of robust execution and accelerating product demand. He notes the surge in US Wegovy pill adoption as a fundamental driver, while acknowledging intensifying competition from Eli Lilly. Technical conditions remain overbought, so momentum may pause in the near term. Still, sentiment and fundamentals both support the underlying uptrend. "As long as NVO holds above $40.87, I remain constructive and expect sideways action before any sustained move higher."

Earlier, analysts noted that while Novo Nordisk demonstrated strong technical momentum, persistent overbought signals increased the risk of a short-term pullback. With the current article highlighting intensified competition and ongoing overbought conditions despite robust results, traders should closely monitor for a potential reversal if support at $40.87 fails to hold.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.